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Abstract
Introduction: Virtually all individuals with Down syndrome (DS) will develop
Alzheimer’s disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers
have characterized AD pathology in cohorts of late-onset AD (LOAD) and autosomaldominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS.
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Methods: CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho-tau181 (ptau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid
cells 2 (sTREM2), chitinase-3-like protein 1 (YKL-40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal-associated protein 25 (SNAP-25), and visinin-like protein 1
(VILIP-1) were assessed in CSF from 44 adults with DS from the Alzheimer’s Biomarker
Consortium–Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene (APOE) ε4 carrier status.
Results: Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with
increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers.
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Discussion: The profile of many established and emerging CSF biomarkers of AD in a
cohort of adults with DS was similar to that reported in LOAD and ADAD, while some
differences were observed.
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1

BACKGROUND

biomarkers in ADAD and LOAD cohorts that significantly correlate
with pathologic and clinical markers of disease progression. These

Due to the triplication of the amyloid precursor protein (APP) gene

emerging biomarkers include markers of neuronal and axonal injury

located on chromosome 21, virtually all individuals with Down syn-

(visinin-like protein 1 [VILIP-1] and neurofilament light chain [NfL]),6,7

drome (DS) will develop brain pathology indicative of Alzheimer’s dis-

synaptic dysfunction (synaptosomal-associated protein 25 [SNAP-

ease (AD) by the age of 40.1 The incidence of AD dementia among

25] and neurogranin [Ng]),

older adults with DS has been observed to be as high as 77% by

like protein 1 [YKL-40] and soluble triggering receptor expressed on

the seventh decade of life.2 However, due to varying baseline or pre-

myeloid cells 2 [sTREM2]).11-13 In LOAD and ADAD cohorts, these

morbid levels of intellectual disability, early detection of the clini-

emerging biomarkers are positively correlated with each other and

cal symptoms of AD is challenging in this population. In late-onset

with levels of CSF tau and p-tau, and they have been shown to be

AD (LOAD) and autosomal dominant AD (ADAD) cohorts, longitudi-

predictive of future cognitive decline, especially in the presence of

nal analysis of various AD biomarkers has revealed significant poten-

amyloid.14 In addition to these markers, α-synuclein (αSyn), which is

tial for their use in determining pathological disease stage, as well

typically associated with Lewy body pathology in Parkinson disease,

as predicting symptom onset and cognitive decline in individuals

has also been associated with AD pathology and cognitive decline.15,16

with pre-clinical

disease.3,4

This pre-symptomatic stage has been esti-

mated to begin two to three decades before the onset of clinical
symptoms.5

8-10

and neuroinflammation (chitinase-3-

Few studies have characterized these emerging biomarkers in adults
with DS.17-19
The Alzheimer’s Biomarker Consortium–Down Syndrome (ABC-

In addition to the established AD cerebrospinal fluid (CSF) biomark-

DS) study aims to identify and track biomarkers of AD progression

ers amyloid beta 1-40 (Aβ40), amyloid beta 1-42 (Aβ42), total tau,

in adults with DS and further characterizes the contributing biolog-

and phospho-tau181 (p-tau), recent studies have identified novel

ical factors that will be critical for early diagnosis, disease staging,
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and development of effective interventions in this high-risk population.
The purpose of this study is to present the cross-sectional analysis of

HIGHLIGHTS

CSF biomarkers of established and novel AD biomarkers in this cohort
and examine biomarker relationships with age, cognitive status, and

1. Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s dis-

apolipoprotein E (APOE) ε4 status (the strongest genetic risk factor for

ease (AD) were assessed in a multisite cohort of adults

LOAD).20

with Down syndrome (DS)
2. CSF AD biomarkers are associated with mild cognitive
impairment (MCI) and dementia in adults with DS

2

3. Adults with DS exhibit CSF biomarker profiles similar to

METHODS

those of other AD cohorts

2.1

4. CSF markers of amyloid and neuronal injury show

Participants

apolipoprotein E gene (APOE) ε4 effects in DS

Adults with DS between 25 and 66 years of age were enrolled in
the ABC-DS study, a multi-site longitudinal study of AD biomarkers
in adults with DS that includes the collection of neuropsychological,

5. APOE ε4 influences levels of CSF amyloid beta42 (Aβ42),
tau, and synaptosomal-associated protein 25 (SNAP-25)
in adults with DS

neuroimaging, genetic, and fluid biomarker measures. Participants with
baseline CSF collections (ages 30 to 61 years) as of January 2019 were
included in this analysis. Informed consent was obtained from all participants where possible; otherwise, assent was obtained from the participant and informed consent obtained from the participant’s proxy

RESEARCH IN CONTEXT

or legally authorized representative. All ABC-DS protocols and procedures were approved by the institutional review boards at the respec-

1. Systematic review: Few studies evaluating cerebrospinal
fluid (CSF) biomarkers of Alzheimer’s disease (AD) in

tive local clinical performance sites.

adults with Down syndrome (DS) have been published.
Therefore, all relevant articles on PubMed relating to CSF

2.2

Cognitive assessment and genetic analysis

biomarkers of AD in other risk groups were also considered.

Using a consensus-based procedure, participants were given the following baseline diagnosis: (1) cognitively stable (CS); (2) mild cognitive
impairment (DS-MCI); (3) possible/probable dementia (DS-AD); or (4)
uncertain. A consensus conference includes at least three individuals
with clinical training and expertise in evaluating dementia in adults with
DS (eg, psychologist, physician), each of whom had participated in the
clinical assessment of a given participant. A diagnosis of CS indicates
no evidence of clinically significant cognitive decline, with performance
consistent with preclinical intellectual functioning and age. A diagnosis
of DS-MCI indicates evidence of cognitive decline over time beyond
what would be expected with age but of insufficient severity to suggest
dementia. A diagnosis of DS-AD indicates evidence of substantial
decline of breadth and severity greater than indicative of DS-MCI or

2. Interpretation: There are commonalities in the profile of
and relationship among CSF biomarkers in adults with DS
compared to those published in other AD cohorts. Therefore, these biomarkers may have potential use in determining pathological disease stage and predicting symptom onset and cognitive decline in individuals with DS, as
has been reported in late-onset and autosomal dominant
forms of AD.
3. Future directions: Investigation of within-person longitudinal change in biomarkers and cognition across the full
disease spectrum in adults with DS are needed. A direct
comparison between adults with DS and other at-risk
groups would be of great value to the field.

clear evidence of substantial cognitive and functional decline with
a high degree of confidence in the dementia rating. Diagnoses were
made using information from core neuropsychological and informant
measures (Down Syndrome Mental Status Examination, Extended &

cases, the karyotype status of adults with DS was obtained from family

Block Design, Verbal Fluency, Berry-Buktenica Test of Visual Motor

members who had medical records with chromosomal analysis results.

Integration, Vineland Adaptive Behavior Scale–Third Edition, Demen-

When the karyotype status was unavailable from medical records,

tia Questionnaire for People with Learning Disabilities, Reiss Screen

blood samples were sent to a designated cytogenetics laboratory at

for Maladaptive Behavior), neurological exam, medical history, and

each medical center. DNA samples were genotyped for two APOE

record review, generally consistent with the recommendations of the

single-nucleotide polymorphisms (SNPs; rs429358 and rs7412) with

American Association on Mental Retardation-International Associa-

the KASP genotyping system by LGC Genomics. Genotype data for

tion for the Scientific Study of Intellectual Disability (AAMR-IASSID)

these two SNPs were used to define APOE ε2, ε3, and ε4 alleles. For this

Working Group for the Establishment of Criteria for the Diagnosis of

analysis, we assigned APOE ε4 status as APOE ε4 negative (non-carriers)

Dementia in Individuals with Developmental

Disability.21,22

In most

or APOE ε4 positive (carriers of at least one copy of the APOE ε4 allele).
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TA B L E 1

Demographics of a cohort of adults with DS with available CSF

Characteristic

All DS (n = 44)

CS (n = 28)

DS-MCI (n = 7)

DS-AD (n = 7)

Age, years

48 ± 7.5

47 ± 7.4

52 ± 4.1

54 ± 5.0

Female/male (% female)

17/27 (39%)

10/18 (36%)

1/6 (14%)

APOE-ε4 carriers

16 (36%)

10 (36%)

2 (29%)

4 (57%)

Trisomy 21

36 (82%)

24 (86%)

5 (71.4%)

5 (71.4%)

Mosaicism

2 (4.5%)

2 (7%)

0 (0%)

0 (0%)

Translocation

2 (4.5%)

1 (3.5%)

1 (14.3%)

0 (0%)

Missing

4 (9%)

1 (3.5%)

1 (14.3%)

2 (28.6%)

Aβ40 (pg/mL1 )

13610 ± 4161

14143 ± 4279

13336 ± 3067

10987 ± 2164

Aβ42 (pg/mL2 )

909 ± 329

978 ± 279

802 ± 148

563 ± 104

a

Total Tau (pg/mL3 )

637 ± 437

564 ± 412

657 ± 385

994 ± 486

a

p-Tau (pg/mL4 )

89.1 ± 75.8

69.9 ± 69.2

110.8 ± 75.4

157.9 ± 71.6

Aβ42/Aβ40 ratio5

0.068 ± 0.019

0.072 ± 0.019

0.061 ± 0.011

0.052 ± 0.009

a

Tau/Aβ42 ratio6

0.856 ± 0.805

0.644 ± 0.527

0.827 ± 0.473

1.921 ± 1.221

a

c

a

5/2 (71%)

b

Karyotype

CSF Biomarkers

p-Tau/Aβ42 ratio7

0.127 ± 0.141

0.086 ± 0.104

0.141 ± 0.092
a

a

0.306 ± 0.19

a

NfL (pg/mL )

2031 ± 1646

1747 ± 1823

2215 ± 712

αSyn (pg/mL9 )

1971 ± 823

1873 ± 807

2387 ± 807

1871 ± 546

sTREM2 (pg/mL10 )

947 ± 334

897 ± 300

1035 ± 376

1044 ± 407

YKL-40 (ng/mL )

249 ± 124

222 ± 135

267 ± 92

327 ± 92

Ng (pg/mL12 )

4549 ± 2507

4144 ± 2368

5742 ± 3144

5107 ± 2004

SNAP-25 (pg/mL )

4.38 ± 1.86

4.16 ± 1.86

4.87 ± 2.08

5.45 ± 1.18

VILIP-1 (pg/mL14 )

195 ± 93

180 ± 82

245 ± 123

230 ± 92

8

11

13

3267 ± 1167

a

a

a

Age and biomarker data are reported as mean ± standard deviation (SD). Two individuals for whom data for consensus diagnosis were not available at the
time of analysis were excluded from the cognitive groups. Biomarker analyses by cognitive group were conducted using Kruskal-Wallis and Dunn tests with
Holm-Bonferroni correction for multiple comparisons. Outliers more than 2 SD from the mean were excluded from statistical analysis but are reported in the
graphs and figures. P values <.05 were considered statistically significant.
a
Denotes significant difference from CS.
b
Denotes significance from DS-MCI.
c
Denotes significance from DS-AD. Superscripted numbers identify the number of outliers (values ± 2 SD from the group means) that were included in the
calculations of the means but omitted from the statistical analyses: 1 n = 1 in CS; 2 n = 2 in CS; 3 n = 2 in CS; 4 n = 1 in CS; 5 n = 1 in CS; 6 n = 1 in CS; 7 n = 2 in CS;
8
n = 1 in CS; 9 n = 1 in CS; 10 n = 3 in CS; 11 n = 1 in CS; 12 n = 1 in CS; 13 n = 2 in CS, n = 1 in DS-MCI; 14 n = 1 in CS.

2.3

CSF collection and analysis

platform (LUMIPULSE G1200, Fujirebio, Malvern, PA) according to
manufacturer’s specifications. Ng, SNAP-25, and VILIP-1 were mea-

Participants underwent CSF collection via lumbar puncture (LP)

sured with microparticle-based immunoassays using Single Molecule

between 9 am and 4 pm; typically, 10 to 20 mL of CSF was collected

Counting technology employing antibodies developed in the labo-

under gravity flow or by aspiration while the participant was sitting,

ratory of Dr. Jack Ladenson at Washington University in St. Louis,

lying, or prone for fluoroscopy-assisted collection. Samples were col-

as described previously.8,10,23 Concentrations of sTREM2 were mea-

lected into a sterile polypropylene tube, flash frozen on dry ice, and

sured via an in-house enzyme-linked immunosorbent assay (ELISA) as

shipped to the ABC-DS Biomarker Core at Washington University in

described previously.12 NfL (UmanDiagnostics, Umeå, Sweden), YKL-

St. Louis. Samples were thawed on wet ice, aliquoted (0.5 mL) into

40 (Quidel, San Diego, CA), and αSyn (ADx Neurosciences, Ghent,

polypropylene tubes, flash frozen, and stored at −80◦ C until biomarker

Belgium) were measured via commercial ELISAs according to man-

analysis. Frozen aliquots were thawed on wet ice the day of analy-

ufacturer recommendations. Because αSyn levels in the blood are

sis. Concentrations of Aβ40, Aβ42, total tau, and p-tau were measured

much higher than in the CSF, hemoglobin was measured as a

by chemiluminescent enzyme immunoassay using a fully automated

control for blood contamination via ELISA (Bethyl Laboratories,
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F I G U R E 1 Distribution of AD biomarkers in a cohort of adults with DS by cognitive status. Levels of (A) Aβ42, (B) total tau, (C) p-tau, (D)
Aβ42/Aβ40 ratio, (E) tau/Aβ42 ratio, (F) p-tau/Aβ42 ratio, (G) YKL-40, (H) SNAP-25, and (I) logNfL are plotted as a function of cognitive status.
Open symbols represent cognitively stable individuals (CS), gray symbols represent individuals with MCI (DS-MCI), and black symbols represent
individuals with AD dementia (DS-AD) defined by consensus criteria. Horizontal lines represent mean ± SD. Outliers more than 2 SD from the
mean (triangles) were excluded from statistical analysis. Group comparisons were conducted using Kruskal-Wallis and Dunn tests with
Holm-Bonferroni correction for multiple comparisons. P values <.05 were considered statistically significant
Montgomery, TX).24 Hemoglobin concentrations were not correlated

3

RESULTS

with αSyn concentrations in the present study, therefore all αSyn data
are reported.

3.1

Demographics

Demographic data are reported in Table 1. Forty-four participants

2.4

Statistical analysis

(mean age 48 ±7.5 years, range 30 to 61 years) had baseline CSF collections as of January 2019. Overall, more male than female partic-

Group comparisons based on cognitive status (CS, DS-MCI, or DS-

ipants underwent CSF collections. The CS and DS-MCI groups were

AD) were performed using Kruskal-Wallis and Dunn tests with Holm-

predominantly male. The DS-AD group was predominantly female

Bonferroni correction for multiple comparisons. Group comparisons

and significantly older than the CS group. APOE-ε4 carriers made up

based on APOE ε4 carrier status (APOE ε4 positive or APOE ε4 neg-

roughly a third of the cohort overall, but a higher proportion of the

ative) were conducted using a Mann-Whitney U test with Holm-

dementia group (57%) were APOE-ε4 carriers. Karyotyping revealed

Bonferroni correction for multiple comparisons and analysis of covari-

36 individuals (82%) with trisomy 21, two with mosaicism, and two

ance (ANCOVA) with age as a covariate (for which we report adjusted

with translocation. Four individuals were missing karyotype informa-

P-values). For these group comparisons, outliers ± two standard devia-

tion; however, a clinical diagnosis of DS was established. A higher

tions (SD) from the group means were excluded from statistical analy-

number of participants were classified as CS (ie, cognitive abilities

sis but were included in the figures for illustrative purposes. Biomarker

not differing from usual as defined by neuropsychological and infor-

correlations are presented as Spearman rho. P values <.05 were con-

mant measures) compared to those who showed cognitive decline

sidered statistically significant.

from a prior evaluation. Data for diagnosis was unavailable for two
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TA B L E 2

Correlation matrix of AD biomarkers in a cohort of adults with DS
Aβ40

Aβ42

tau

p-tau

NfL

sTREM2

YKL-40

αSyn

Ng

SNAP-25

VILIP-1

ρ

−0.13

−0.47

0.29

0.55

0.60

0.29

0.64

0.24

0.30

0.32

0.43

P

n.s.

Biomarker
Age

Aβ40

Aβ42

<.01

.055

<.001

<.0001

.060

<.0001

n.s.

<.05

<.05

<.01

ρ

0.63

0.21

0.29

−0.05

0.42

0.31

0.76

0.60

0.41

0.52

P

<.0001

n.s.

.058

n.s.

<.01

.053

<.0001

<.0001

<.01

<.001

ρ

−0.32

−0.44

−0.49

0.08

−0.27

0.14

−0.04

−0.16

−0.11

P

<.05

<.01

<.001

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

tau

ρ

0.72

0.74

0.31

0.55

0.54

0.61

0.57

0.56

P

<.0001

<.0001

<.05

<.001

<.001

<.0001

<.0001

<.001

p-tau

ρ

0.71

0.47

0.79

0.73

0.83

0.70

0.83

P

<.0001

NfL

sTREM2

YKL-40

αSyn

<.01

<.0001

<.0001

<.0001

<.0001

<.0001

ρ

0.44

0.59

0.38

0.48

0.45

0.42

P

<.01

<.001

<.05

<.01

<.01

<.01

ρ

0.54

0.56

0.58

0.32

0.43

P

<.001

<.001

<.001

<.05

<.01

ρ

0.68

0.73

0.56

0.77

P

<.0001

<.0001

<.001

<.0001

ρ

0.93

0.61

0.82

P

<.0001

<.0001

<.0001

Ng

ρ

0.65

0.84

P

<.0001

SNAP-25

ρ

0.75

P

<.0001

<.0001

Correlation coefficients represent Spearman rho (ρ). P values <.05 were considered statistically significant. White cells are not significant (n.s.). Lightest gray
are significant with P ≤ .06; light gray are significant with P < .05; medium gray are significant with P < .01; dark gray are significant with P < .001; darkest gray
are significant with P < .0001.

individuals (both trisomy 21), so biomarker data for these participants

3.3

Biomarker distributions by age

were not included in analyses based on cognitive status, but they were
included in analyses evaluating biomarker correlations and effects of
APOE ε4 status.

In addition, the biomarker levels were also assessed with respect to age
at time of LP (Table 2, Figure 2). Aβ42 (ρ = −0.47, P < .01) was negatively
correlated with age, whereas levels of p-tau (ρ = 0.55, P < .0001), NfL
(ρ = 0.60, P < .0001), YKL-40 (ρ = 0.64, P < .0001), Ng (ρ = 0.30, P < .05),

3.2

Biomarker distributions by cognitive status

SNAP-25 (ρ = 0.32, P < .05), and VILIP-1 (ρ = 0.55, P < .01) were all positively correlated with age. Total tau (ρ = 0.29, P = .055) and sTREM2

Individuals were grouped according to cognitive status (CS, DS-MCI, or

(ρ = 0.29, P = .060) exhibited a trend toward significance with respect

DS-AD), and mean biomarker levels were compared (Table 1, Figure 1).

to age, but these analytes were highly variable in this cohort. Aβ40 (ρ =

Concentrations of Aβ42 and the Aβ42/Aβ40 ratio were significantly

−0.13, P = .40) and αSyn (ρ = 0.24, P = .12) were not significantly cor-

lower in individuals with dementia (P = .001 and P = .020, respec-

related with age in this cohort.

tively), and total tau, YKL-40, and SNAP-25 levels were significantly
higher in the DS-AD group compared to the CS group (P = .009, P =
.007, and P = .025, respectively). Of all the biomarkers, only NfL and

3.4

APOE effects

the p-tau/Aβ42 ratio were significantly higher in both DS-MCI and DSAD groups (P = .0002 and P = .0001, respectively) compared to the CS

We examined CSF biomarkers by APOE ε4 carrier status by designat-

group. Levels of p-tau, αSyn, sTREM2, Ng, and VILIP-1 were not signifi-

ing individuals as APOE ε4-positive or -negative (Figure 3). Levels of

cantly different among the groups, although the lack of significance was

sTREM2, SNAP-25, and the tau/Aβ42 ratio were significantly higher

likely due more to the high variability than the difference in the mean

in those who were APOE ε4-positive versus ε4-negative (P = .024,

concentrations.

P = .035, and P = .049, respectively). After controlling for age, Aβ42,
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F I G U R E 2 Distribution of AD biomarkers in a cohort of adults with DS by age and cognitive status. Levels of (A) Aβ42, (B) total tau, (C) p-tau,
(D) Aβ42/Aβ40 ratio, (E) tau/Aβ42 ratio, (F) p-tau/Aβ42 ratio, (G) YKL-40, (H) SNAP-25, and (I) logNfL are plotted as a function of age at LP. Open
symbols represent cognitively stable individuals (CS), gray symbols represent individuals with MCI (DS-MCI), and black symbols represent
individuals with AD dementia (DS-AD) defined by consensus criteria. Correlations coefficients represent Spearman rho (ρ). P values <.05 were
considered statistically significant and are shown.

total tau, SNAP-25 and the tau/Aβ42 ratio were significantly different

4

DISCUSSION

between carriers and non-carriers (adjusted P = .008, P = 0.027, P =
.028, and 0.015, respectively). Significant APOE ε4–associated differ-

This report describes results of the initial cross-sectional analysis of

ences in other biomarkers were not observed (all P > .05).

CSF biomarker data in the multi-site ABC-DS study. Due to the limited number of studies of CSF biomarkers related to risk for AD in
adults with DS, sample sizes were not formally constructed, and all

3.5

Biomarker correlations

participants with available CSF collections were included in the analysis. Despite the small number of participants with available CSF (n

The correlation among CSF biomarkers in the cohort as a whole was

= 44), the AD biomarker profiles in this cohort of adults with DS are

also assessed (Table 2). Aβ40 was significantly positively correlated

remarkably similar to those observed in LOAD and ADAD cohorts.5,14

with Aβ42 (ρ = 0.63, P < .0001), sTREM2 (ρ = 0.42, P < .01), αSyn (ρ =

In general, low CSF Aβ42 and the Aβ42/Aβ40 ratio (indicative of amy-

0.64, P < .0001), Ng (ρ = 0.30, P < .05), SNAP-25 (ρ = 0.32, P < .05), and

loid deposition) were observed in individuals with AD dementia (com-

VILIP-1 (ρ = 0.43, P < .01). Aβ42 was negatively correlated with tau (ρ =

pared to the MCI and CS groups), while biomarkers of tauopathy (p-

−0.32, P < .05), p-tau (ρ = −0.44, P < .01), and NfL (ρ = −0.49, P < .001).

tau) and neurodegeneration (total tau, NfL) were higher. This is con-

Total tau, p-tau, NfL, sTREM2, YKL-40, αSyn, Ng, SNAP-25, and VILIP-

sistent with findings in other cohorts of adults with DS,17,18,25 as well

1 were all positively correlated with each other (P < .05, P < .01, P <

as ADAD and LOAD.14 CSF NfL and the p-tau/Aβ42 ratio were the

.001, or P < .0001 for all). For illustrative purposes, select correlations

only markers that significantly differentiated both the DS-AD and DS-

are shown in Figure 4.

MCI groups from the CS group, despite the relatively high variability
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F I G U R E 3 Distribution of CSF biomarkers by age and APOE ε4 carrier status. Levels of (A) Aβ42, (B) total tau, (C) the tau/Aβ42 ratio, and (D)
SNAP-25 are plotted as a function of age at LP. Open circles and dotted lines represent APOE ε4 non-carriers (ε4-). Black circles and solid lines
represent APOE ε4 carriers (ε4+). Lines are linear regressions of biomarker data by age at LP. One individual did not have APOE genotype data and
was excluded from this analysis. Group comparisons were performed by ANCOVA with age as a covariate. Adjusted P values <.05 were considered
statistically significant

in absolute values of both markers (Figure 1). Fortea et al. reported

In this small study of adults with DS, we found that presence of an

high diagnostic performance of CSF Aβ42, p-tau, and NfL in a larger

APOE ε4 allele was associated with significantly lower CSF Aβ42 and

cohort of adults with DS.17 Further analysis is required to determine

higher SNAP-25, tau and the tau/Aβ42 ratio, even after controlling for

the diagnostic utility of these biomarkers at the individual subject level

age. A previous study of LOAD in cognitively normal older adults in the

in the present cohort. Results in the two cohorts may differ given that

preclinical stage also reported similar APOE ε4 effects on CSF Aβ42;

the CS group in the present study is expected to be diminished due

however, CSF tau was not affected by APOE ε4 status, likely due to the

to rapid biomarker changes observed in the fifth decade of life in CS

very early disease stage in that solely preclinical cohort.30 Higher CSF

adults with DS. As expected, several biomarkers were significantly cor-

levels of SNAP-25 were recently associated with APOE ε4 carrier sta-

related with age in adults with DS, consistent with data from other AD

tus in LOAD.31 To our knowledge, this is the first study to evaluate the

cohorts.14

With respect to age, it seems that most, if not all, of the

APOE genotype effects on these biomarkers in DS. The mechanisms

biomarkers are already changing at the ages examined in this cohort,

underlying these associations remain to be determined. Future stud-

suggesting the need to include even younger participants in the study,

ies should include APOE genotype as an important variable to consider

who would be expected to be earlier in the evolution of the disease

when evaluating the role of apoE across the cognitive aging spectrum

process. The high variability in levels of tau and SNAP-25 as a func-

in DS.

tion of age suggests that there may be additional processes taking

The correlation profile of the various CSF biomarkers in this cohort

place in individuals with DS. Longitudinal analysis will be necessary

of adults with DS was consistent with other reports in LOAD and

to elucidate individual changes over time, but in this cross-sectional

ADAD,5,32 with strong positive correlations among the various mark-

analysis, it appears that CSF Aβ42 concentrations are still declining

ers of neuronal injury but less with Aβ markers, thus potentially sup-

(indicative of continuing amyloid deposition), and measures of tauopa-

porting commonality in the underlying pathologic processes among

thy and neurodegeneration are exhibiting robust increases, by age ≈40

different forms of genetic and sporadic AD. However, there are

(Figure 2).

some differences. The relatively large positive correlation (ρ = 0.63)

The presence of the APOE ε4 allele is a strong risk factor for

observed between Aβ40 and Aβ42 in DS likely reflects the overex-

the development of LOAD, as well as for an earlier onset of clini-

pression and overproduction of APP and its resultant Aβ peptides due

cal symptoms of dementia.20,26 The APOE genotype has also similarly

to triplication of chromosome 21. Reductions in Aβ42, but not Aβ40,

been reported to influence age of symptom onset in ADAD mutation

with advancing age likely reflect the AD-associated aggregation and

carriers.27-29 Whether APOE genotype also influences CSF biomarker

deposition of Aβ42 as amyloid plaques. Analyses of the associa-

profiles in ADAD remains to be determined.

tion between CSF biomarkers and amyloid imaging in the ABC-DS
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F I G U R E 4 Scatter plots of select biomarker correlations. Plotted are the relationships between levels of (A) Aβ42 and Aβ40, (B) Aβ42 and
total tau, (C) Aβ42 and p-tau, (D) total tau and p-tau, (E) total tau and log NfL, (F) p-tau and YKL-40, (G) Ng and αSyn, (H) Ng and VILIP-1, and (I)
p-tau and SNAP-25. Correlation coefficients represent Spearman rho (ρ). P values <.05 were considered statistically significant.

cohort are ongoing and will provide a direct test of this hypoth-

21–related effects. Heterogeneity in CSF sample collection procedures

esis. Although markers of neuroinflammation (sTREM2 and YKL-

(eg, method and timing of LP) in ABC-DS may also influence analyte

40) were more strongly correlated with markers of neuronal injury

recovery, notably Aβ peptides known to exhibit diurnal variability.34

than markers of amyloid (Aβ42), the causality remains to be deter-

However, the use of the ratio of CSF Aβ42/Aβ40 as a marker of amy-

mined. Of particular note is the very high positive correlation (ρ =

loid helps reduce this potential effect.

0.93) observed between CSF αSyn and Ng. This finding is supported

Our understanding of the timing of pathologic processes that

by a report that these proteins may be binding partners at the

develop over the entire natural course of AD (from CS through

synapse.33 It is likely that a similarly high correlation will also be

stages of cognitive and functional decline) has been made possible

observed in LOAD and/or ADAD, but this has yet to be reported.

by biomarker evaluation. Recent data from the largest international

If consistently observed in other cohorts, this would support the

ADAD cohort (Dominantly Inherited Alzheimer Network, DIAN)

use of CSF levels of αSyn as a potential biomarker of synaptic

demonstrated abnormalities in CSF markers of all pathologic pro-

dysfunction.

cesses (including amyloid, tau, neuronal injury, synaptic dysfunction,

This study has several limitations. Although large for cohorts of

and neuroinflammation) in AD mutation carriers during the 20 to

individuals with DS, the small sample size limits the statistical power

30 year asymptomatic/preclinical period, with CSF concentrations

required to identify differences of small magnitude and to allow proper

of biomarkers increasing in abnormality as individuals approached

control for potentially important covariates. The small number also

their estimated age of symptom onset.5 Despite challenges unique to

reduces our ability to draw conclusions that may be generalizable to

the DS population (eg, heterogeneity in premorbid cognitive abilities,

the DS population as a whole. Lack of an age-matched comparator

heterogeneity in the prevalence and age-of-onset of dementia, and

control group without DS limits our ability to define general trisomy

existence of comorbidities due to the triplication of chromosome 21),
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longitudinal clinical and biomarker studies such as ABC-DS are critical
to better define AD-related processes that will enable early diagnosis,
disease staging, elucidation of clinically relevant targets for clinical
trials, and eventually, the discovery of effective interventions in this
high-risk population.
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